DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-220/SLR-022

Berlex, Inc.
Attention: Micheal Cammarata
Manager, Global Regulatory Affairs
P.O. Box 1000
Montville, NJ 07045-1000

Dear Mr. Cammarata:

Please refer to your supplemental new drug application dated March 24, 2005, received March 25, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Ultravist® (brand of iopromide) Injection.

We acknowledge receipt of your submission dated March 24, 2005.

This "Changes Being Effected in 30 days" supplemental new drug application provides for the following change to the container label:

1. (b)(4) g the currently used (b)(4) with the (b)(4)
2. The 100 mL vials of Ultravist® incorporate a corporate branded graphic.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the submitted labeling (immediate container submitted March 24, 2005).

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 20-220/SLR-022.** Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Renee C. Tyson, Regulatory Project Manager, at (301) 827-7510.

Sincerely,

{See appended electronic signature page}

Eldon E. Leutzinger, Ph.D.
Chemistry Team Leader
Division of Medical Imaging and
Hematology Products
HFD-160
DNDC II, Office of New Drug Chemistry
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Eldon Leutzinger
8/12/05 11:42:52 AM